Tigecycline (Tigecycline) Patent Expiration, LOE Window & CMS Spending

Tigecycline (Tigecycline) by Amneal Pharmaceuticals: FDA Orange Book LOE 2033-04-07, 6 AB generics, $3.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmneal Pharmaceuticals
FDA Application & PathwayN211158 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-04-07
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$3.2M
2024 Medicare Part D Spend$2.4M
2024 Medicaid Spend$766K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel